Literature DB >> 26826462

Genetic analysis and functional characterization of novel mutations in a series of patients with atypical hemolytic uremic syndrome.

Nóra Szarvas1, Ágnes Szilágyi1, Dorottya Csuka1, Beáta Takács1, Krisztina Rusai2, Thomas Müller2, Klaus Arbeiter2, Marienn Réti3, Ágnes Haris4, László Wagner5, Szilárd Török5, Kata Kelen6, Attila J Szabó6, György S Reusz6, B Paul Morgan7, Zoltán Prohászka8.   

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a rare disorder caused by dysregulation of the complement alternative pathway, and associated with mutations in genes of complement components and regulators. In the recent years several studies have been published describing these mutations, however, no data is available from the Central and Eastern European region. In this study we present a detailed genetic analysis of our 30 patients, hospitalized with the diagnosis of aHUS in the past 7 years. We analyzed the genetic variants of genes CFH, CFI, CD46, THBD, CFB and C3; furthermore the possible effect of mutations that may alter the function or level of factor H protein was also investigated. We identified 27 (12 novel and 15 previously described) potentially disease-causing mutations in the candidate genes in 23 patients. Genetic analysis of family members revealed that in most cases the disease develops in individuals with multiple genetic risk factors, which may explain the low penetrance of the mutations. Here we showed that two novel mutations (p.W198R, p.P1161T) and a previously reported one (p.R1215Q) in CFH caused impaired regulation as indicated by increased lysis in hemolytic test, while four CFH mutations (p.V609D, p.S722X, p.T1216del and p.C448Y) were associated with decreased factor H protein level in serum as determined by allele-specific immunoassay. These results further point to the necessity of complete genetic workup of patients with aHUS and to the importance of functional characterization of novel variations.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Atypical hemolytic uremic syndrome; CFH; Complement; Mutation; Y402H

Mesh:

Substances:

Year:  2016        PMID: 26826462     DOI: 10.1016/j.molimm.2016.01.003

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  15 in total

Review 1.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

2.  Targeted exome sequencing in anti-factor H antibody negative HUS reveals multiple variations.

Authors:  R W Thergaonkar; Ankita Narang; Bahadur Singh Gurjar; Pradeep Tiwari; Mamta Puraswani; Himanshi Saini; Aditi Sinha; Binuja Varma; Mitali Mukerji; Pankaj Hari; Arvind Bagga
Journal:  Clin Exp Nephrol       Date:  2017-09-22       Impact factor: 2.801

3.  Decreased Neutrophil Extracellular Trap Degradation in Shiga Toxin-Associated Haemolytic Uraemic Syndrome.

Authors:  Jonatan Leffler; Zoltán Prohászka; Bálint Mikes; György Sinkovits; Katarzyna Ciacma; Péter Farkas; Marienn Réti; Kata Kelen; György S Reusz; Attila J Szabó; Myriam Martin; Anna M Blom
Journal:  J Innate Immun       Date:  2016-10-27       Impact factor: 7.349

4.  Functional Characterization of the Disease-Associated N-Terminal Complement Factor H Mutation W198R.

Authors:  Marcell Cserhalmi; Barbara Uzonyi; Nicolas S Merle; Dorottya Csuka; Edgar Meusburger; Karl Lhotta; Zoltán Prohászka; Mihály Józsi
Journal:  Front Immunol       Date:  2017-12-13       Impact factor: 7.561

Review 5.  The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment.

Authors:  Maartje J Geerlings; Eiko K de Jong; Anneke I den Hollander
Journal:  Mol Immunol       Date:  2016-12-06       Impact factor: 4.407

6.  Atypical hemolytic uremic syndrome precipitated by thyrotoxicosis: a case report.

Authors:  Ling Hou; Yue Du
Journal:  BMC Pediatr       Date:  2020-04-17       Impact factor: 2.125

7.  Sex Differences in Clinical Presentation and Outcomes among Patients with Complement-Gene-Variant-Mediated Thrombotic Microangiopathy.

Authors:  Christof Aigner; Martina Gaggl; Renate Kain; Zoltán Prohászka; Nóra Garam; Dorottya Csuka; Raute Sunder-Plassmann; Leah Charlotte Piggott; Natalja Haninger-Vacariu; Alice Schmidt; Gere Sunder-Plassmann
Journal:  J Clin Med       Date:  2020-03-31       Impact factor: 4.241

8.  Primary pneumococcal peritonitis can be the first presentation of a familial complement factor I deficiency1.

Authors:  S Ugrinovic; H Firth; D Kavanagh; T Gouliouris; P Gurugama; H Baxendale; P J Lachmann; D Kumararatne; E Gkrania-Klotsas
Journal:  Clin Exp Immunol       Date:  2020-07-24       Impact factor: 4.330

Review 9.  Complement in Secondary Thrombotic Microangiopathy.

Authors:  Lilian Monteiro Pereira Palma; Meera Sridharan; Sanjeev Sethi
Journal:  Kidney Int Rep       Date:  2020-10-21

10.  Effect of rare coding variants in the CFI gene on Factor I expression levels.

Authors:  Sarah de Jong; Elena B Volokhina; Anita de Breuk; Sara C Nilsson; Eiko K de Jong; Nicole C A J van der Kar; Bjorn Bakker; Carel B Hoyng; Lambert P van den Heuvel; Anna M Blom; Anneke I den Hollander
Journal:  Hum Mol Genet       Date:  2020-08-11       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.